Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ozanimod study in moderately to severely active ulcerative colitis
MOH_2022-05-03_010620Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ozanimod in autoimmune colitis (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Efficacy of ozanimod in pediatric active ulcerative colitis. Started Feb 2022; status: recruiting.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2022-05-03_010620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-03_010620.